Pharmaceutical Executive
The Business Magazine of Pharma. Vol 28, Number
« Real innovation is the name of the game—products and technologies that specifically meet a previously unmet medical need, and therefore unequivocally attract needed funding. Market access and maintenance are knowledgebased, cross-functional processes, which leading pharma companies must implement immediately ».
November, 2008
Value Destruction
Financial Advisory
Q4 - 2008
Global Vaccine Commercializatio
Part One: Competitive Challenge
Claude Allary, Maxime Riché, and Meredith Edwards
October, 2008
Global pharmaceutical, generics and biotech industry news
Article EAP
Alain Gilbert, Vanessa Caignault and Murielle Foist of Bionest Partners explain why European EAPs are worth considering by pharma/biotech companies.
October, 2008
Stratégies pour l’innovation pharmaceutique
Expertise Pharmacie
« Et si la crise actuelle avait finalement des conséquences positives pour les laboratoires et leur potentiel d'innovation ? » Claude Allary, directeur général de Bionest Consultants, et Julian Ozdowski, senior consultant, s'attachent à analyser les transformations profondes de l'innovation pharmaceutique, notamment grâce à des accords de portée considérable avec les entreprises de biotechnologie.
October, 2008
Financial Advisory Newsletter
Q3 - 2008
Influenza: the Avoidable Killer
SCRIP Drug Market developments Influenza is a disease of global health significance against which the fight is far from over.
Claude Allary & Dr Meredith Edwards
July, 2008
Pharma Deals
Pharmaceutical Executive Many say licensing is the new R&D. The thrid quarter of 2007 featured some pricey cherry-picking. Will the unions bear fruit? We've the intersting ones to watch.
Daniel Teper
Private Equity Newsletter
Private Equity
1st Semester 2008 Review.
April, 2008
Cornering the EU Market: the need for Creative Strategies
EBR When it comes to the accessibility of the EU pharmaceutical market, it is clear that a number of factors have changed in the past few years. Evolution or revolution?
Alain J Gilbert and Mark Larkin
Spring, 2008
1 2 3 4 5